Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein
Catalog No: KRASG12V-HB007
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi at the C-TerminusIt contains Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M), VVGAVGVGK peptide (accession: NP_002107
Product overview
Recombinant Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-TerminusIt contains Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and VVGAVGVGK peptide (accession: NP_002107.3(HLA-A*03:01) & P61769(B2M) &VVGAVGVGK).
Product Details
- Molecular Aliases
- MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 50.09 kDa. Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer is greater than 95% as determined by SEC-HPLC.
Background
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
References
- (1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.